Table 3 Most common AEs of any grade (occurring in ≥15% or an AE of special interest [AESI]) or grade 3/4 (occurring in ≥5%, safety population)^a.

Event	Lyophilised belantamab mafodotin 3.4 mg/kg (n = 24)
	Number of patients (%)
	Any grade	Grade 3/4
Keratopathy (MECs)^b	23 (96)	18 (75)
Thrombocytopenia^c	11 (46)	5 (21)
Fatigue	11 (46)	0
Blurred vision^d	9 (38)	2 (8)
Anaemia	6 (25)	4 (17)
Dry eye^e	6 (25)	0
Back pain	6 (25)	1 (4)
Hyponatraemia	5 (21)	1 (4)
Intraocular pressure increased	5 (21)	0
Headache	5 (21)	1 (4)
Aspartate aminotransferase increased	5 (21)	0
Decreased appetite	5 (21)	0
Hypercalcaemia	4 (17)	3 (13)
Blood lactate dehydrogenase increased	4 (17)	0
Pyrexia^f	4 (17)	1 (4)
Upper respiratory tract infection	4 (17)	0
Infusion-related reactions^f	4 (17)	0
Hypophosphataemia	3 (13)	3 (13)
Neutropenia^g	2 (8)	2 (8)

AE adverse event, AESI adverse event of special interest, BCVA best-corrected visual acuity, KVA keratopathy and visual acuity, MECs microcyst-like epithelial change.
Listed in order of decreasing frequency of any grade events.
^aEvents graded using the Common Terminology Criteria for Adverse Events criteria v4.03, with the exception of keratopathy (MECs)²¹.
^bCorneal epithelium changes (an AESI) were observed on eye examination with or without changes in BCVA from baseline or symptoms. Graded per KVA scale.
^cThrombocytopenia (an AESI) includes preferred terms thrombocytopenia, haematoma and platelet count decreased.
^dBlurred vision includes preferred terms vision blurred, diplopia and visual acuity reduced.
^eDry eye includes preferred terms dry eye and eye pruritus.
^fInfusion-related reactions (an AESI) includes preferred terms infusion-related reaction, pyrexia, transfusion reaction and chills occurring ≤24 h of infusion.
^gNeutropenia includes neutropenia and neutrophil count decreased.

Quick links

Search